Pfizer and Moderna Stocks Crash as Senate Advances RFK Jr for Health Secretary

Shares of vaccine giants Moderna and Pfizer plunged on Tuesday as the Senate advanced Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services.

Moderna’s stock dropped nearly 6% immediately following the committee vote, while Pfizer and BioNTech also saw substantial losses.

Kennedy, a longtime advocate for medical freedom and government transparency, has vowed to overhaul the nation’s public health agencies, restoring trust and prioritizing the well-being of Americans over corporate profits.

His nomination represents a seismic shift away from the influence of Big Pharma and towards a system that values informed consent, rigorous safety protocols, and accountability.

As head of HHS, Kennedy plans to increase oversight of the pharmaceutical industry, ensuring that vaccine and drug development processes are transparent and science-driven rather than profit-motivated.

He has pledged to investigate potential regulatory failures and conflicts of interest within the FDA and CDC, institutions that have faced mounting criticism for their close ties to the companies they regulate.

Kennedy has also expressed a commitment to defending individual health choices. His stance against coercive medical policies resonates with millions of Americans who felt marginalized during the pandemic-era mandates.

With childhood vaccination rates declining and public skepticism growing, Kennedy aims to rebuild trust in health recommendations by fostering open scientific debate and eliminating corporate influence over federal health agencies.

Critics argue that Kennedy’s leadership could deter Americans from receiving vaccines, but his supporters see this as fearmongering by an industry that has thrived on mandates and liability protections. By promoting transparency and informed decision-making, Kennedy hopes to empower citizens to take control of their health without undue pressure from powerful corporate interests.

With the full Senate set to vote on his confirmation, RFK Jr. is on the brink of ushering in a new era for public health—one that prioritizes safety, transparency, and personal freedom over the unchecked power of pharmaceutical giants. His leadership at HHS could mark the beginning of long-overdue reforms, holding vaccine manufacturers accountable and restoring integrity to the nation’s health policies.